CGEM
Income statement / Annual
Last year (2024), Cullinan Therapeutics, Inc.'s total revenue was $0.00,
and the percentage change from the previous year is not available.
In 2024, Cullinan Therapeutics, Inc.'s net income was -$167.38 M.
See Cullinan Therapeutics, Inc.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
| Period Ended |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
| Operating Revenue |
$0.00 |
$0.00 |
$0.00 |
$18.94 M |
$0.00 |
$0.00 |
$0.00 |
| Cost of Revenue |
$306.00 K
|
$0.00
|
$0.00
|
$0.00
|
$62.00 K
|
$70.00 K
|
$43.00 K
|
| Gross Profit |
-$306.00 K
|
$0.00
|
$0.00
|
$18.94 M
|
-$62.00 K
|
-$70.00 K
|
-$43.00 K
|
| Gross Profit Ratio |
0
|
0
|
0
|
1
|
0
|
0
|
0
|
| Research and Development Expenses |
$142.90 M
|
$148.16 M
|
$91.95 M
|
$57.75 M
|
$43.21 M
|
$16.79 M
|
$9.58 M
|
| General & Administrative Expenses |
$52.82 M
|
$42.49 M
|
$40.19 M
|
$29.15 M
|
$17.12 M
|
$5.48 M
|
$5.00 M
|
| Selling & Marketing Expenses |
$894.00 K
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$53.71 M
|
$42.49 M
|
$40.19 M
|
$29.15 M
|
$17.12 M
|
$5.48 M
|
$5.00 M
|
| Other Expenses |
$0.00
|
$440.00 K
|
-$276.79 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Operating Expenses |
$196.61 M
|
$191.09 M
|
-$144.65 M
|
$86.90 M
|
$60.34 M
|
$22.27 M
|
$14.59 M
|
| Cost And Expenses |
$196.92 M
|
$191.09 M
|
-$144.65 M
|
$86.90 M
|
$60.34 M
|
$22.27 M
|
$14.59 M
|
| Interest Income |
$29.66 M
|
$21.63 M
|
$6.61 M
|
$477.00 K
|
$888.00 K
|
$620.00 K
|
$397.00 K
|
| Interest Expense |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Depreciation & Amortization |
$306.00 K
|
$310.00 K
|
$93.00 K
|
$53.00 K
|
$62.00 K
|
$70.00 K
|
$43.00 K
|
| EBITDA |
-$167.15 M |
-$190.34 M |
-$132.04 M |
-$67.90 M |
-$60.27 M |
-$22.20 M |
-$14.54 M |
| EBITDA Ratio |
0
|
0
|
0
|
-3.58
|
0
|
0
|
0
|
| Operating Income Ratio |
0
|
0
|
0
|
-3.59
|
0
|
0
|
0
|
| Total Other Income/Expenses Net |
$29.46 M
|
$21.87 M
|
$6.67 M
|
$469.00 K
|
$877.00 K
|
$616.00 K
|
$397.00 K
|
| Income Before Tax |
-$167.46 M
|
-$169.22 M
|
$151.32 M
|
-$67.49 M
|
-$59.46 M
|
-$21.65 M
|
-$14.19 M
|
| Income Before Tax Ratio |
0
|
0
|
0
|
-3.56
|
0
|
0
|
0
|
| Income Tax Expense |
$117.00 K
|
-$14.12 M
|
$42.12 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Net Income |
-$167.38 M
|
-$153.16 M
|
$111.21 M
|
-$65.57 M
|
-$51.80 M
|
-$20.04 M
|
-$14.19 M
|
| Net Income Ratio |
0
|
0
|
0
|
-3.46
|
0
|
0
|
0
|
| EPS |
-3.11 |
-3.69 |
2.46 |
-1.48 |
-1.19 |
-19.7 |
-17.74 |
| EPS Diluted |
-3.11 |
-3.69 |
2.38 |
-1.48 |
-1.19 |
-19.68 |
-17.74 |
| Weighted Average Shares Out |
$53.77 M
|
$41.51 M
|
$45.16 M
|
$44.29 M
|
$43.52 M
|
$1.02 M
|
$800.00 K
|
| Weighted Average Shares Out Diluted |
$53.77 M
|
$41.55 M
|
$46.64 M
|
$44.29 M
|
$43.52 M
|
$1.02 M
|
$800.04 K
|
| Link |
|
|
|
|
|
|
|
